797PDLATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO). (23rd October 2018) - Matsubara, N; Chi, K N; Ozguroglu, M; Rodriguez Antolin, A; Feyerabend, S; Fein, L; Alekseev, B Y; Sulur, G; Protheroe, A; Li, S; Mundle, S D; De Porre, P; et al.